Filing Flows › Puma Biotechnology (PBYI) › Operating margin
Puma Biotechnology (PBYI) operating margin by quarter
Puma Biotechnology's operating margin was 9.6% in Q3 2026 (third quarter 2026), -3.8 pts from Q2 2026. Over the last 6 quarters it ranged from 8.7% (Q1 2025) to 22.7% (Q4 2025).
| Quarter | Operating margin | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | 9.6% | -3.8 pts | -8.0 pts |
| Q2 2026 | 13.4% | -9.2 pts | +0.8 pts |
| Q4 2025 | 22.7% | +5.1 pts | — |
| Q3 2025 | 17.6% | +4.9 pts | — |
| Q2 2025 | 12.7% | +4.0 pts | — |
| Q1 2025 | 8.7% | — | — |
Q3 2026 at a glance
Puma Biotechnology, Q3 2026: revenue $55.1M (+1% year over year), operating margin 9.6%, net earnings $6.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is Puma Biotechnology's operating margin?
Puma Biotechnology's operating margin was 9.6% in Q3 2026 (third quarter 2026), -3.8 pts from Q2 2026.
How has Puma Biotechnology's operating margin changed?
Over the last 6 quarters it ranged from 8.7% (Q1 2025) to 22.7% (Q4 2025).